This mechanism may explain the positive response to tamoxifen observed in this study, in which a patient with an ERβ-positive prolactinoma exhibited the greatest reduction in prolactin level and tumor shrinkage in response to tamoxifen treatment. The gene discussed is ESR2; the disease is neoplasm.